Why Some People Don't Feel Edibles

Plain-Language Summary

If you've eaten a 10 mg gummy, waited four hours, and felt nothing, you're not imagining it and you're not alone. Surveys and clinician reports consistently describe a subset of users who report little or no effect from oral THC at doses that strongly affect others Weak / limited^[1].

There are four plausible reasons this happens, in rough order of likelihood:

1. The dose was too low for you. Oral THC has notoriously variable bioavailability — somewhere between 4% and 20% of what you swallow actually reaches your bloodstream Strong evidence^[2].
2. Your liver metabolizes THC unusually. Variants in the CYP2C9 enzyme change how much 11-hydroxy-THC — the metabolite that does most of the work — you produce Strong evidence^[3].
3. The product wasn't what the label said. Independent testing has repeatedly found edibles with wildly inaccurate THC content Strong evidence^[4].
4. Tolerance. Regular flower or vape use blunts edible response too.

> This is not medical advice. Talk to a clinician familiar with cannabis before changing any medication regimen or escalating doses, especially if you take other prescription drugs.

What Probably Explains It (Stronger Evidence)

CYP2C9 genetic variation

THC is metabolized in the liver primarily by CYP2C9 and CYP3A4. The CYP2C9 pathway produces 11-hydroxy-THC (11-OH-THC), a metabolite that crosses the blood-brain barrier readily and is, in human studies, roughly as potent or more potent than THC itself Strong evidence^[3][5].

People carrying the CYP2C93 variant have reduced enzyme activity. In a controlled pharmacokinetic study, 3/3 homozygotes had ~3x higher THC exposure and stronger sedation than 1/*1 'normal' metabolizers after oral THC Strong evidence^[3]. The interesting flip side: 'ultra-rapid' or normal metabolizers may convert THC and clear it so efficiently that peak effects are blunted, though this specific 'fast metabolizer = no effect' claim is more inferred than directly proven Weak / limited.

First-pass metabolism and bioavailability

Swallowed THC passes through the gut wall and liver before reaching circulation. Oral bioavailability is low and highly variable across individuals — published estimates range from 4% to 20% Strong evidence^[2][6]. A 10 mg dose might deliver an effective 0.5 mg to one person and 2 mg to another.

Product inaccuracy

Multiple lab audits in legal markets have found edibles with THC content significantly different from the label — sometimes under by 50% or more Strong evidence^[4]. If your '10 mg' gummy actually contains 3 mg, non-response isn't biology, it's manufacturing.

Fed vs. fasted state

THC is highly lipophilic. Taking edibles with a high-fat meal increases absorption substantially in pharmacokinetic studies of dronabinol and similar formulations Strong evidence^[7]. Taking an edible on a completely empty stomach can blunt and delay effects.

What Might Explain It (Weaker Evidence)

Endocannabinoid tone

The theory: people with naturally high baseline endocannabinoid activity have downregulated CB1 receptors and respond less to exogenous THC. There's some preclinical support and indirect human data, but no clean clinical test for this in edible non-responders Weak / limited.

Tolerance from other routes

Daily flower or concentrate users develop measurable CB1 downregulation that recovers over weeks of abstinence Strong evidence^[8]. This applies to edibles too — heavy inhaled users often need much larger oral doses.

Gut microbiome

The microbiome influences drug metabolism generally, and there is speculation it affects cannabinoid absorption. As of now, this is largely hypothesis, not data No data.

Anxiety, expectation, and set

If you're tense and watching the clock, mild effects can pass unnoticed. This isn't 'all in your head' as a dismissal — expectancy effects are real and measurable in psychoactive drug research Weak / limited.

What Doesn't Hold Up

• 'Indica edibles don't work on me but sativa does.' The indica/sativa distinction does not reliably predict effects, and once cannabis is decarboxylated and infused into an edible, most of the volatile terpene profile that drove that folklore is gone or radically altered Disputed.
• 'Eat a mango first.' The myrcene-from-mango idea is folklore. There is no controlled human evidence that dietary myrcene meaningfully alters THC effects No data.
• 'Your liver is just too strong.' A loose pop-science version of the CYP2C9 story. The real picture involves specific enzyme variants, not generic 'strong liver' Disputed.
• 'Hold it under your tongue and it'll absorb sublingually.' Standard gummies and baked goods are formulated for GI absorption, not sublingual; meaningful sublingual uptake requires specific formulations (tinctures, films, lozenges) Weak / limited.

What We Don't Know

• The full distribution of edible non-response in the general population — no large epidemiological study has measured it.
• Whether CYP3A4 inducers (St. John's Wort, rifampin, some anticonvulsants) routinely cause clinically meaningful edible non-response Weak / limited.
• Whether nanoemulsion 'fast-acting' edibles bypass enough of the variability to make non-responders into responders. Marketing claims outpace the published data Weak / limited.
• Whether some people simply lack subjective sensitivity to 11-OH-THC at the receptor level.

Comparison With Standard Approaches

For medical patients who don't respond to edibles, clinicians typically consider:

• Inhaled cannabis (vaporized flower). Bypasses first-pass metabolism. Onset in minutes, much more predictable dosing, but shorter duration Strong evidence^[6].
• Sublingual tinctures and oromucosal sprays (e.g., nabiximols/Sativex where available). Partial avoidance of first-pass metabolism; more reliable than gummies for some patients Strong evidence^[9].
• Dronabinol (Marinol) or nabilone. FDA-approved synthetic oral THC analogs. Same first-pass issue as edibles but with standardized dosing Strong evidence.
• Dose titration. For non-responders confirmed not to be in a tolerance state, careful upward titration under guidance is the standard approach.

None of this should be self-directed if you have cardiovascular disease, psychiatric history, or take interacting medications.

Risks of 'Pushing Through' Non-Response

The single most common cannabis-related ER visit pattern is edible overconsumption: someone feels nothing at 90 minutes, takes another dose, and is hit with the combined load 2–4 hours later Strong evidence^[10]. Symptoms include severe anxiety, panic, vomiting, tachycardia, and (rarely) transient psychosis.

If you're a CYP2C9 slow metabolizer who also assumed you were a non-responder, the consequences of redosing can be especially rough — that's exactly the genotype that produces sustained, intense exposure Strong evidence^[3].

Practical rules of thumb (not medical advice):

• Wait at least 2 hours, ideally 3, before considering more.
• Try a verified-tested product before concluding you don't respond.
• Take with food.
• If you genuinely don't respond at 20–25 mg from a tested product on two separate occasions, edibles probably aren't your route — talk to a clinician about alternatives.

> Reminder: This article is educational, not medical advice. Cannabis interacts with many prescription drugs (warfarin, clobazam, tacrolimus, and others). Consult a qualified clinician before using cannabis medicinally.

Sources

How this page was made